Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $141000.0.

  • Compass Therapeutics' Other Accumulated Expenses fell 1556.89% to $141000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $141000.0, marking a year-over-year decrease of 1556.89%. This contributed to the annual value of $621000.0 for FY2024, which is 15875.0% up from last year.
  • As of Q3 2025, Compass Therapeutics' Other Accumulated Expenses stood at $141000.0, which was down 1556.89% from $384000.0 recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Other Accumulated Expenses ranged from a high of $621000.0 in Q4 2024 and a low of $137000.0 during Q1 2023
  • Its 3-year average for Other Accumulated Expenses is $290818.2, with a median of $274000.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in Compass Therapeutics' Other Accumulated Expenses was 15875.0% (2024), while the steepest drop was 5728.9% (2024).
  • Quarter analysis of 3 years shows Compass Therapeutics' Other Accumulated Expenses stood at $240000.0 in 2023, then skyrocketed by 158.75% to $621000.0 in 2024, then crashed by 77.29% to $141000.0 in 2025.
  • Its Other Accumulated Expenses stands at $141000.0 for Q3 2025, versus $384000.0 for Q2 2025 and $274000.0 for Q1 2025.